Comparative bioavailability study of a generic naltrexone tablet preparation

Drug Development and Industrial Pharmacy

Volumn 25, Issue 3, 1999, Pages 353-356

  Yuen, Kah Hay ^a   Peh, Kok Khiang ^a   Billa, Nashiru ^a  

^a SCHOOL OF PHARMACEUTICAL SCIENCES   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; NALTREXONE; NARPAN; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; TABLET FORMULATION;

ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DRUGS, GENERIC; HUMANS; MALE; NALTREXONE; NARCOTIC ANTAGONISTS;

EID: 0344629281     PISSN: 03639045     EISSN: None     Source Type: Journal    
DOI: 10.1081/DDC-100102181     Document Type: Article

References (15)

1. National Clearinghouse for Drug Abuse Information, Fact Sheet on Naltrexone, Series 38(1), National Institute on Drug Abuse, Rockville, MD, December 1978.
2. W. R. Martin and D. R. Jasinki, Clin. Pharm. Ther., 14, 142 (1973).
3. S. Taylor, R. Rodgers, R. Lynn, and N. Gerber, J. Pharmacol. Exp. Ther., 213, 289 (1980).
4. M. E. Wall, D. R. Brian, and M. Perez-Reyes, Drug Metab. Disposition, 9, 370 (1981).
5. K. K. Peh, N. Billa, and K. H. Yuen, J. Chromatogr. B, 701, 140 (1997).
6. M. Gibaldi and D. Perrier, Pharmacokinetics, 2nd ed., Marcel Dekker, New York, 1982, p. 145.
7. J. G. Wagner, in Fundamentals of Clinical Pharmacokinetics, 1st ed., Drug Intelligence Publication, Hamilton, IL, 1975, p. 285.
8. K. Verebey, J. Volavka, S. J. Mule, and R. B. Resnick, Clin. Pharmacol. Ther., 20, 315 (1980).
9. U.S. Pharmacopoeial Convention, USP D1, in Drug Information for the Health Care Professional, 14th ed., Author, Rockville, MD, 1994, p. 1982.
10. W. J. Westlake, in Biopharmaceutical Statistics for Drug Development (K. E. Peace, ed.), Marcel Dekker, New York, 1988, p. 329.
11. U.S. Pharmacopoeial Convention, The United States Pharmacopoeia XXXIII, Author, Rockville, MD, 1995.
12. E. Diletti, D. Haushcke, and V. W. Steinijans, Int. J. Clin. Pharmacol. Ther. Toxicol., 29, 1 (1991).
13. D. L. Weiner, in Statistics in the Pharmaceutical Industry (C. R. Buncher and J. Y. Tsay, eds.), Marcel Dekker, New York, 1981, p. 205.
14. A. Sioufi, N. Sandrenan, J. Godbillon, P. Trunet, C. Czendlik, H. Howald, Ch. Pfister, and F. Ezzet, Biopharm. Drug Disp., 18(6), 489 (1997).
15. C. N. Chiang, L. E. Hollister, A. Kishimoto, and G. Barnett, Clin. Pharmacol. Ther., 36, 704 (1984).